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Abstract
Background We analysed cell-free DNA (cfDNA) in the
plasma of patients with both malignant and benign breast
lesions by real-time quantitative PCR to determine whether
the Wnding may have diagnostic and prognostic implications.
Methods Plasma samples were obtained from 33 patients
with breast cancer, 32 patients with benign breast lesions
and 50 healthy women as normal controls. Circulatory
cfDNA was extracted from the plasma samples and quanti-
Wed by real-time quantitative PCR for the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene.
Results The mean concentrations of cfDNA in the plasma
samples from patients with breast cancer, patients with
benign breast lesions and normal controls were 2,285,
1,368 and 1,489 genome equivalents (GE) per millilitre,
respectively. The level of cfDNA in the breast cancer group
was signiWcantly higher than those in the benign lesion
group and control group (P = 0.007 and 0.013, respec-
tively). These Wndings were associated with malignant
tumour size. The levels of the cfDNA were high in patients
with lymph node involvement and distant metastasis.
Conclusions Our results suggest that levels of cfDNA in
the plasma are elevated in malignant breast cancer and cor-
related with tumour size. These Wndings could have diag-
nostic and prognostic value for malignant breast tumours.
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Introduction
Breast cancer is the most common malignant disease in
women and the second leading cause of cancer death in
Western industrial countries. Early diagnosis of breast can-
cer and accurate identiWcation of haematogenic metastases
can improve the success of treatment [1–4]. Therefore, the
detection of single tumour cell shedding in the blood in early
stage cancer could help physicians choose the optimal ther-
apy for patients. In addition, accurate quantiWcation of meta-
static tumour cells could help physicians adjust the level of
treatment. Determination of occult metastases at later stages
or after primary treatment of the disease could assist in mon-
itoring and following the progress of the disease. Many hos-
pitals and institutes have performed the detection of
disseminated tumour cells in bone marrow of patients with
breast cancer [5–8]. A number of studies suggested that the
detection of disseminated single tumour cells in bone mar-
row in primary breast cancer could eventually replace lymph
node dissection in patients with small tumours and no clini-
cal signs of lymph node involvement [4, 7]. However, the
risks of invasive bone marrow aspiration have made its rou-
tine implementation in screening, tracking and follow-up of
patients with breast cancer problematic.
The discovery of cell-free DNA in plasma and serum
samples provides another possibility to examine tumour
derived genetic materials in the circulation and to detect
haematogenic spread of tumour cell DNA [9]. Qualitative
alterations in circulating DNA, such as microsatellite alter-
ations [10], oncogene mutations [11], mitochondrial DNA,
tumour-speciWc methylated DNA [12] and viral DNA [13],
have been found in patients with diVerent types of cancer.
Quantitative alterations of circulating cfDNA have also
been observed in several cancers, such as prostate cancer
[14], lung cancer [15], pancreatic cancer [16], leukaemia
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328 Arch Gynecol Obstet (2007) 276:327–331and lymphoma [17]. High levels of circulating cfDNA were
correlated with tumour metastasis, response to therapy and
recurrence [15, 18].
Therefore, tumour-derived circulating nucleic acids in
the plasma or serum of cancer patients were introduced as a
tool for detection and surveillance of cancers [19].
In our study, we present a quantiWcation of cell-free
plasma DNA in patients with malignant and benign breast
lesions. The concentration of these circulating molecules in
the cohort of breast cancer was compared with those in nor-
mal controls and in the patients with benign lesions. We
analysed the correlation between the levels of cell-free
plasma DNA in patients with breast cancer and the tradi-
tional staging parameters and clinical predictive markers.
Materials and methods
Sample collection
In total, 115 peripheral blood samples were recruited in this
study, which included samples from 32 patients with
benign breast lesions and 33 patients with malignant breast
cancer at the University Women’s Hospital in Basel, Swit-
zerland. The remaining 50 samples from healthy female
patients without disease were used as controls. All diagno-
ses were biopsy-conWrmed. The samples had been collected
before any invasive procedures had been performed or any
therapy had been administered. The clinical characteristics
of the study cohorts are shown in Table 1.
The study was approved by the institutional review
board of the University of Basel. Written informed consent
was obtained in all cases.
DNA extraction
About 10 ml of peripheral blood from each subject were sent
to our laboratory after blood draw and processed immedi-
ately by centrifugation at 1,600g for 10 min. The plasma lay-
ers were transferred to new Eppendorf tubes and centrifuged
again at maximum speed (16,000g) for 10 min. Cell-free
plasma DNA was extracted from 400 l plasma sample using
the high pure PCR Template Preparation Kit (Roche Diag-
nostics, Germany) according to the manufacturer’s protocol.
The DNA preparations were eluted in 100 l elution buVer.
The eluted DNA was stored at ¡20°C until further use.
Quantitative analysis of cell-free DNA in plasma samples
A total of 5 l of DNA elution were used as template for
the TaqMan real time PCR analysis. The amount of cell-
free plasma DNA was quantiWed using the following
primer pairs and VIC labelled TaqMan MGB-probe for
GAPDH gene (GenBank Accession No. J04038):
Forward: 5 CCCCACACACATGCACTTACG 3
Reverse: 5 CCTAGTCCCAGGGCTTTGATT 3
Probe 5 (MGB): GTG AAC GTG GAT GAA GTT
GG (VIC) 3
Our standard TaqMan PCR conditions have been described
in our previous publications, involving 40 cycles of 15 s at
95°C and 1 min at 60°C [20]. The cell-free plasma DNA
equivalents were calculated according to very reproducible
standard dilution curves using a known concentration of
human genomic DNA. The concentrations of cell-free
plasma DNA were expressed as genome-equivalents (GE)
per millilitre of plasma.
Statistical analysis
Data were analysed with the SPSS software (Statistical
Software Package for Windows). The Mann-Whitney U-
test was used to compare the levels of cell-free plasma
DNA in diVerent groups categorized by normal healthy
individuals, benign tumour group and breast cancer. The
Pearson test was used to analyse the relationships between
levels of cell-free plasma DNA and other established prog-
nostic factors in breast cancer.
Results
Levels of cell-free plasma DNA in the three study groups
The results in Table 1 show that the mean concentrations of
cell-free plasma DNA in the samples of healthy controls,
Table 1 CfDNA in the plasma samples of normal individuals and patients with benign lesions and breast cancer
Data are presented as mean and range (in the parentheses). SigniWcance was determined by the Mann–Whitney U test
Control group Benign lesion Breast cancer P (1:2/1:3/2:3)
1 2 3
Cases 50 32 33
Age 54 (33–79) 42 (20–91) 59.5 (34–96) 0.001/0.12/0.000
Plasma DNA (GE/ml) 1,489 (298–12,030) 1,368 (404–13,682) 2,285 (602–20,636) 0.697/0.013/0.007123
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1,489, 1,368 and 2,285 GE/ml, respectively. In breast can-
cer cases, the level was signiWcantly elevated when com-
pared to benign breast lesions and healthy controls
(P = 0.013 and 0.007, respectively) (Fig. 1). No signiWcant
diVerence was found between the control group and the
benign lesion group. In the study group of benign lesions,
the patients were younger than those in the control group.
We subdivided the benign lesion group into two diVerent
age cohorts, namely a younger group and an age-matched
group to the controls. We compared the concentration of
cell-free plasma DNA between the control group and age-
matched benign lesion group, and control group and youn-
ger benign lesion group. No signiWcant diVerences were
found.
Correlation between levels of cell-free plasma DNA 
and other established prognostic factors
In the cohort of breast cancer, associations between levels
of cell-free plasma DNA and traditional clinical parame-
ters, such as tumour size, lymph node involvement, extent
of metastasis, histological grades, receptor status and HER-
2/neu were analysed.
Elevated levels of cell-free plasma DNA were found to
be associated with tumour size (Fig. 2, Table 2). The level
of cell-free plasma DNA was signiWcantly higher in the
patients with breast cancer with a tumour size >2 cm than
in those with a tumour size <2 cm (3,556 GE/ml vs.
1,470 GE/ml, P = 0.013) (Fig. 2).
In this study, lymph node involvement was present in 11
cases. The level of cell-free plasma DNA was overall
higher in the nodal positive patients than in the nodal nega-
tive patients (Fig. 3), but no statistical signiWcant diVerence
was found between the two groups.
Distant metastases were found in 2 of 33 patients. The
concentrations of the cell-free plasma DNA in the two
cases amounted to 4,416 and 5,294 GE/ml, respectively,
which were two folds higher than the mean concentration
of cell-free plasma DNA in the overall cohort of breast can-
cer cases (2,285 GE/ml) (Fig. 3). The cumulative percent-
ages of the two cases in the cohort of breast cancer were 84
and 87%.
Oestrogen and progesterone are involved in breast can-
cer growth. Hormone receptors are measured to guide clini-
cal hormonal therapy. In our study, both the oestrogen and
progesterone receptor status in the tumour tissues of the
patients with breast cancer were examined by immunohis-
tochemistry. Positive oestrogen and progesterone receptors
were found in 29 of the 33 cases. The receptor-positive
tumour cells in tumour tissues ranged from 10 to 100%.
The level of cell-free plasma DNA did not correlate with
the percentage of oestrogen and progesterone receptors.
HER-2/neu (also called erbB-2) encodes a transmem-
brane tyrosine kinase receptor. The ampliWcation of HER-
2/neu can serve as a predictive factor in breast cancer. In
our study, 7 of the 29 cases showed HER-2/neu ampliWca-
Fig. 1 Box plot indicating cell-free plasma DNA levels in normal
individuals and patients with benign lesion and breast cancer The
medians are indicated by a line inside each box, the 25th and 75th per-
centiles by the box limits; the lower and upper error bars represent the
10th and 90th percentiles, respectively
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Fig. 2 Box plot indicating cell-free plasma DNA levels in breast can-
cer, in which the tumour size is less than 2 cm (T1) or more than 2 cm
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Table 2 CfDNA in the plasma samples of patients with breast cancer
is elevated with increased tumour size
Data are presented as mean and range (in parentheses). SigniWcance
was determined by the Mann–Whitney U test
T1 Tumour size is less than 2 cm; T2 tumour size is more than 2 cm
Tumour size T1 T2 P
Cell-free plasma DNA 
(GE/ml)
1,470 
(603–15,714)
3,556 
(1,162–20,636)
0.013123
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DNA in the seven cases were not higher than in the other 22
cases, which were negative for HER-2/neu.
The histological grade of breast cancer, based on the fre-
quency of cell mitosis, tubule formation and nuclear pleo-
morphism serves as a predictive factor. The level of cell-
free plasma DNA in the cohort of grade I cases was not sig-
niWcantly diVerent from the level in the cohorts of grade II
or III cases.
Discussion
In this study, we found that the level of cell-free plasma
DNA is elevated in patients with breast cancer. From these
results, several questions arise. First, what is the origin of
these circulatory molecules and the mechanism behind their
increase? Second, what roles do they play in patients with
breast cancer? Third, can the high level of the plasma DNA
in breast cancer be used as a marker for patients in screen-
ing, early diagnosis, identiWcation of metastases and/or fol-
low-up testing?
Our experiences with cell-free fetal DNA and fetal cells
in the maternal circulation may help to answer the Wrst
question. Preeclampsia is a pregnancy related disorder and
is caused by apoptotic–necrotic shedding of cell-free debris
from placental ischaemia into the maternal circulation. We
found that both cell-free fetal and maternal DNA was
increased in the preeclampsia [20]. The increments of both
the cell-free fetal and maternal DNA levels corresponded to
the degree of disease severity [20]. In addition, cell-free
fetal DNA increased prior to the onset of preeclampsia, but
not cell-free maternal DNA [21]. The number of fetal cells
in the maternal circulation was also elevated in preeclamp-
sia, but did not correlate with amount of cell-free fetal DNA
in maternal plasma in preeclampsia [22]. However, cell-free
fetal DNA has been found to be associated with placental
syncytiotrophoblast microparticles (STBM), which are
released into maternal blood stream during pregnancy [23].
The results suggest that exaggerated shedding of placental
apoptotic and/or necrotic materials might be the main
source of the high level of the cell-free fetal DNA, and also
that the exaggerated inXammatory response and inappropri-
ate endothelial activation of preeclampsia might be the
main source of the high concentration of the maternal DNA.
Along similar lines, the high level of cell-free plasma DNA
in breast cancer could result from apoptosis and/or necrosis
of tumour tissues. Using a methylation-speciWc tumour
gene as a marker, Jahr et al. [24] were able to discriminate
tumour and nontumour derived DNA in plasma. Tumour-
derived cfDNA amounted to 3% of total cf DNA.
Viruses are encapsulated nucleic acid (DNA or RNA)
that can only replicate in living host cells. Some viruses can
convert normal host cells into tumour cells by viral trans-
formation. Regarding the question of what role cell-free
tumour-derived DNA plays, whether it can play similar role
as viruses in transforming normal cells into malignant cells
remains unclear. Several studies have shown that tumour-
derived DNA could be transferred from one cell to another
via the phagocytosis of apoptotic bodies and is stable over
time, suggesting that tumour-derived DNA plays a possible
role in the development of metastasis, and that stem cells
might be naturally transformed with dominant oncogenes
shedding in the plasma as a result of dissemination [25–28].
Thijssen et al. [18] reported that cell-free serum DNA was
correlated with colorectal liver metastases. Garcia-Olmo
et al. [29] were able to detect cell-free tumour DNA earlier
and more frequently than circulating tumour cells in plasma
samples of metastatic animal models, but neither the detec-
tion of tumour DNA in the plasma nor the presence of cir-
culating tumour cells were strongly correlated with the
presence of metastases.
In reference to the third question posed earlier, we com-
pared the high level of cell-free plasma DNA with other tra-
ditional staging parameters, such as tumour size, lymph
node involvement, extent of metastasis and predictive
markers such as histological grades, receptor status and
HER-2/neu. Tumour size and extent of spread are the most
important factors in predicting the prognosis of a woman
with this disease. High level of cell-free plasma DNA ele-
vated in tumour size was found. A pronounced increase of
cell-free plasma DNA in patients with lymph node involve-
ment and distant metastases was observed.
In conclusion, our data suggest that using a robust Taq-
man real-time PCR, the level of cell-free plasma DNA in
Fig. 3 Box plot indicating cell-free plasma DNA levels in the circula-
tion of the patients with or without lymph node involvement (nodal
positive or nodal negative) and the patients with distant metastases.
The medians are indicated by a line inside each box, the 25th and 75th
percentiles by the box limits; the lower and upper error bars represent
the 10th and 90th percentiles, respectively123
Arch Gynecol Obstet (2007) 276:327–331 331patients with breast cancer can be easily quantiWed and
compared with normal individuals and patients with benign
lesions. This may have diagnostic and prognostic value for
malignant breast tumours. In addition, plasma sampling is
much easier and less painful than bone marrow aspiration.
QuantiWcation of cell-free plasma DNA in patients with
breast cancer could be considered for use in detecting
occult tumour shedding before, during and after treatment.
However, before the transition of a research technique to
clinical use can be achieved, large-scale studies are needed
to clarify the roles of the molecules in metastatic disease
and to verify the value of its application in monitoring dis-
ease and evaluating prognosis. We believe that our Wndings
provide a good platform for such future studies.
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